688767 博拓生物
已收盘 11-05 15:00:00
资讯
新帖
简况
11月4日博拓生物涨5.61%，中银健康生活混合A基金重仓该股
证券之星 · 11-04 17:26
11月4日博拓生物涨5.61%，中银健康生活混合A基金重仓该股
博拓生物（688767）11月3日主力资金净卖出552.09万元
证券之星 · 11-04 09:16
博拓生物（688767）11月3日主力资金净卖出552.09万元
11月3日博拓生物跌5.47%，中银健康生活混合A基金重仓该股
证券之星 · 11-03 17:03
11月3日博拓生物跌5.47%，中银健康生活混合A基金重仓该股
股市必读：博拓生物新发布《2026年第三季度报告》
证券之星 · 11-02
股市必读：博拓生物新发布《2026年第三季度报告》
博拓生物（688767）披露2026年第三季度报告，10月30日股价上涨0.83%
证券之星 · 10-30
博拓生物（688767）披露2026年第三季度报告，10月30日股价上涨0.83%
博拓生物(688767.SH)发布前三季度业绩，归母净损1666.78万元
智通财经 · 10-29
博拓生物(688767.SH)发布前三季度业绩，归母净损1666.78万元
博拓生物新注册《微流控荧光免疫分析仪M1000软件（linux版）V1.0》项目的软件著作权
证券之星 · 10-29
博拓生物新注册《微流控荧光免疫分析仪M1000软件（linux版）V1.0》项目的软件著作权
博拓生物（688767）10月13日主力资金净买入349.72万元
证券之星 · 10-14
博拓生物（688767）10月13日主力资金净买入349.72万元
诺奖光遗传学技术引产业关注，国内多条神经基因治疗管线加速推进
中金财经 · 10-06
诺奖光遗传学技术引产业关注，国内多条神经基因治疗管线加速推进
博拓生物（688767）9月29日主力资金净买入305.47万元
证券之星 · 09-30
博拓生物（688767）9月29日主力资金净买入305.47万元
9月21日杭州博拓生物科技涨6.11%，广发医药创新混合发起式A基金重仓该股
证券之星 · 09-21
9月21日杭州博拓生物科技涨6.11%，广发医药创新混合发起式A基金重仓该股
博拓生物上半年净利转亏 2021上市募9亿国泰海通保荐
中金财经 · 09-10
博拓生物上半年净利转亏 2021上市募9亿国泰海通保荐
每周股票复盘：博拓生物（688767）将召开股东会审议股权激励计划
证券之星 · 09-06
每周股票复盘：博拓生物（688767）将召开股东会审议股权激励计划
股市必读：博拓生物新发布《2026年第二次临时股东会会议资料》
证券之星 · 09-04
股市必读：博拓生物新发布《2026年第二次临时股东会会议资料》
股市必读：博拓生物新发布《2026年第二次临时股东会会议资料》
证券之星 · 09-03
股市必读：博拓生物新发布《2026年第二次临时股东会会议资料》
博拓生物（688767）披露2026年半年度报告，8月31日股价上涨4.35%
证券之星 · 08-31
博拓生物（688767）披露2026年半年度报告，8月31日股价上涨4.35%
股市必读：博拓生物中报 - 第二季度单季净利润同比下降272.88%
证券之星 · 08-31
股市必读：博拓生物中报 - 第二季度单季净利润同比下降272.88%
博拓生物（688767）2026年中报简析：增收不增利，三费占比上升明显
证券之星 · 08-30
博拓生物（688767）2026年中报简析：增收不增利，三费占比上升明显
博拓生物(688767)6月30日股东户数0.64万户，较上期减少20.95%
证券之星 · 08-29
博拓生物(688767)6月30日股东户数0.64万户，较上期减少20.95%
图解博拓生物中报：第二季度单季净利润同比下降272.88%
证券之星 · 08-29
图解博拓生物中报：第二季度单季净利润同比下降272.88%
暂无数据
公司概况
公司名称：
杭州博拓生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2021-09-08
主营业务：
杭州博拓生物科技股份有限公司的主营业务是即时检测试剂及仪器的研发、生产与销售。公司的主要产品是药物滥用（毒品）检测系列、传染病检测系列、生殖健康检测系列、肿瘤标志物检测系列、心肌标志物检测系列、抗原/抗体生物原料、动物疾病检测平台系列、炎症系列、分子诊断平台系列。
发行价格：
34.55
{"stockData":{"symbol":"688767","market":"SH","secType":"STK","nameCN":"博拓生物","latestPrice":38.66,"timestamp":1793862000000,"preClose":37.44,"halted":0,"volume":2042384,"delay":0,"changeRate":0.0326,"floatShares":149000000,"shares":149000000,"eps":0.0692,"marketStatus":"已收盘","change":1.22,"latestTime":"11-05 15:00:00","open":37.05,"high":39.2,"low":37,"amount":78588700,"amplitude":0.0588,"askPrice":38.67,"askSize":35,"bidPrice":38.66,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.0692,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793928600000},"marketStatusCode":5,"adr":0,"adjPreClose":37.44,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793842200000,1793849400000],[1793854800000,1793862000000]],"highLimit":41.18,"lowLimit":33.7,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":149333334,"isCdr":false,"pbRate":2.7,"roa":"--","peRate":558.67052,"roe":"--","epsLYR":0.34,"committee":-0.06383,"marketValue":5773000000,"turnoverRate":0.0137,"status":0,"afterMarket":{"amount":0,"volume":0,"close":38.66,"buyVolume":0,"sellVolume":500,"time":1793864037746,"indexStatus":"已收盘 11-05 15:30:00","preClose":37.44},"floatMarketCap":5773000000},"requestUrl":"/m/hq/s/688767/tweets","defaultTab":"tweets","newsList":[{"id":"2680870039","title":"11月4日博拓生物涨5.61%，中银健康生活混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680870039","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680870039?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:26","pubTimestamp":1793784414,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日博拓生物涨5.61%，收盘报37.44元，换手率1.45%，成交量2.16万手，成交额7850.2万元。重仓博拓生物的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为中银基金的中银健康生活混合A。中银健康生活混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688767"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680704295","title":"博拓生物（688767）11月3日主力资金净卖出552.09万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680704295","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680704295?lang=zh_cn&edition=full","pubTime":"2026-11-04 09:16","pubTimestamp":1793755005,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月3日收盘，博拓生物报收于35.45元，下跌5.47%，换手率1.38%，成交量2.06万手，成交额7462.7万元。近5日资金流向一览见下表：博拓生物融资融券信息显示，融资方面，当日融资买入793.26万元，融资偿还690.8万元，融资净买入102.46万元，连续3日净买入累计324.41万元。博拓生物主营业务：研发、生产和销售高质量的POCT诊断试剂产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400011459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688767","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680949746","title":"11月3日博拓生物跌5.47%，中银健康生活混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680949746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680949746?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:03","pubTimestamp":1793696622,"startTime":"0","endTime":"0","summary":"证券之星消息，11月3日博拓生物跌5.47%，收盘报35.45元，换手率1.38%，成交量2.06万手，成交额7462.7万元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为中银基金的中银健康生活混合A。中银健康生活混合A目前规模为0.6亿元，最新净值1.643，较上一交易日下跌0.07%，近一年上涨21.69%。中银健康生活混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300033734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688767","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680783279","title":"股市必读：博拓生物新发布《2026年第三季度报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2680783279","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680783279?lang=zh_cn&edition=full","pubTime":"2026-11-02 07:49","pubTimestamp":1793576951,"startTime":"0","endTime":"0","summary":"公司公告汇总：博拓生物披露2026年第三季度报告，本报告期归母净利润为-115,206.88元，同比下降101.17%；年初至报告期末归母净利润为-16,667,771.29元，同比下降174.87%。博拓生物第四届董事会第十次会议决议公告杭州博拓生物科技股份有限公司于2026年10月29日召开第四届董事会第十次会议，审议通过《关于2026年第三季度报告的议案》和《关于调整公司内部管理机构的议案》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200002086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688767"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679690216","title":"博拓生物（688767）披露2026年第三季度报告，10月30日股价上涨0.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679690216","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679690216?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:47","pubTimestamp":1793360861,"startTime":"0","endTime":"0","summary":"公司于近日披露《2026年第三季度报告》。报告显示，本报告期营业收入为97,494,250.12元，同比下降6.96%；年初至报告期末累计营业收入312,178,379.69元，同比增长1.33%。本报告期利润总额为221,836.47元，同比下降97.82%；年初至报告期末利润总额为-23,400,803.95元，同比下降202.94%。研发投入占营业收入的比例本报告期为15.61%，减少1.27个百分点；年初至报告期末为21.28%，增加2.56个百分点。总资产本报告期末为2,381,620,520.61元，较上年度末下降6.21%；归属于上市公司股东的所有者权益为2,141,421,951.73元，较上年度末下降9.64%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000049275.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688767"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679177286","title":"博拓生物(688767.SH)发布前三季度业绩，归母净损1666.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679177286","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679177286?lang=zh_cn&edition=full","pubTime":"2026-10-29 22:28","pubTimestamp":1793284097,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博拓生物(688767.SH)披露2026年第三季度报告，前三季度公司实现营收3.12亿元，同比增长1.33%;归母净利润亏损1666.78万元;扣非净利润亏损2229.72万元;基本每股收益-0.11元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688767","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679142629","title":"博拓生物新注册《微流控荧光免疫分析仪M1000软件（linux版）V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2679142629","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679142629?lang=zh_cn&edition=full","pubTime":"2026-10-29 14:18","pubTimestamp":1793254731,"startTime":"0","endTime":"0","summary":"证券之星消息，近日博拓生物（688767）新注册了《微流控荧光免疫分析仪M1000软件（linux版）V1.0》项目的软件著作权。今年以来博拓生物新注册软件著作权2个。结合公司2026年中报财务数据，今年上半年公司在研发方面投入了5121.71万元，同比增28.06%。通过天眼查大数据分析，杭州博拓生物科技股份有限公司共对外投资了7家企业，参与招投标项目374次；财产线索方面有商标信息105条，专利信息249条，著作权信息4条；此外企业还拥有行政许可470个。数据来源：企查查以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900029631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688767","159180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675396869","title":"博拓生物（688767）10月13日主力资金净买入349.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675396869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675396869?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:29","pubTimestamp":1791937789,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，博拓生物报收于38.9元，下跌2.29%，换手率1.63%，成交量2.43万手，成交额9412.77万元。近5日资金流向一览见下表：博拓生物融资融券信息显示，融资方面，当日融资买入1185.43万元，融资偿还730.92万元，融资净买入454.51万元。博拓生物主营业务：研发、生产和销售高质量的POCT诊断试剂产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688767"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673051766","title":"诺奖光遗传学技术引产业关注，国内多条神经基因治疗管线加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2673051766","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673051766?lang=zh_cn&edition=full","pubTime":"2026-10-06 21:30","pubTimestamp":1791293401,"startTime":"0","endTime":"0","summary":"近日，2026 年诺贝尔生理学或医学奖正式揭晓，表彰科学家在光遗传学领域的开创性研究成果，这项颠覆性底层技术火速出圈，引爆资本市场与生物医药行业关注，带动脑科学、神经基因治疗赛道热度全面攀升。业内人士分析，本次诺奖权威背书，将大幅加速光遗传学技术的科研转化与产业普及，进一步兑现赛道价值。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202610/06/20261006119145.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202610/06/20261006119145.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20261006/32388712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","600196","BK0183","BK0196","301293","BK0096","300683","BK0060","BK0239","BK0012","BK0216","603127","BK0175","BK0236","BK0188","688767","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671252312","title":"博拓生物（688767）9月29日主力资金净买入305.47万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671252312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671252312?lang=zh_cn&edition=full","pubTime":"2026-09-30 08:31","pubTimestamp":1790728268,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月29日收盘，博拓生物报收于40.46元，下跌2.03%，换手率1.24%，成交量1.84万手，成交额7504.1万元。近5日资金流向一览见下表：博拓生物融资融券信息显示，融资方面，当日融资买入1481.63万元，融资偿还891.12万元，融资净买入590.51万元，连续3日净买入累计1515.35万元。博拓生物主营业务：研发、生产和销售高质量的POCT诊断试剂产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000006731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688767","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159935","title":"9月21日杭州博拓生物科技涨6.11%，广发医药创新混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159935","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669159935?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:43","pubTimestamp":1789980185,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日杭州博拓生物科技涨6.11%创60日新高，收盘报43.44元，换手率3.7%，成交量5.53万手，成交额2.37亿元。重仓杭州博拓生物科技的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为广发基金的广发医药创新混合发起式A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","BK0239","688767","159938","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666430569","title":"博拓生物上半年净利转亏 2021上市募9亿国泰海通保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2666430569","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666430569?lang=zh_cn&edition=full","pubTime":"2026-09-10 16:57","pubTimestamp":1789030626,"startTime":"0","endTime":"0","summary":"中国经济网北京9月10日讯 博拓生物 近期发布2026年半年度报告。2026年上半年，公司实现营业收入2.15亿元，同比增长5.61%；归属于上市公司股东的净利润-1655.26万元，去年同期为1240.24万元；归属于上市公司股东的扣除非经常性损益的净利润-2080.19万元，去年同期为683.48万元；经营活动产生的现金流量净额为811.44万元。 博拓生物首次公开发行募集资金总额为9.21亿元，募集资金净额为8.29亿元，较原拟募资少6207.81万元。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/10/20260910129553.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/10/20260910129553.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260910/32366180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK1564","BK0184","BK0201","BK0183","BK0276","BK1147","688767","BK0028","BK0239","601211","IPOS","02611","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665365044","title":"每周股票复盘：博拓生物（688767）将召开股东会审议股权激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2665365044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665365044?lang=zh_cn&edition=full","pubTime":"2026-09-06 02:44","pubTimestamp":1788633849,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，博拓生物报收于37.5元，较上周的37.0元上涨1.35%。本周关注点公司公告汇总：博拓生物将于2026年9月14日召开临时股东会，审议2026年限制性股票激励计划及相关议案。公司公告汇总杭州博拓生物科技股份有限公司将于2026年9月14日召开第二次临时股东会，审议《公司2026年限制性股票激励计划（草案）》及其摘要、《公司2026年限制性股票激励计划实施考核管理办法》及提请股东会授权董事会办理股权激励相关事宜的议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688767"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664806408","title":"股市必读：博拓生物新发布《2026年第二次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664806408","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664806408?lang=zh_cn&edition=full","pubTime":"2026-09-04 02:14","pubTimestamp":1788459252,"startTime":"0","endTime":"0","summary":"公司公告汇总：博拓生物将于2026年9月14日召开第二次临时股东会，审议2026年限制性股票激励计划相关议案。公司公告汇总2026年第二次临时股东会会议资料杭州博拓生物科技股份有限公司将于2026年9月14日召开第二次临时股东会，审议《公司2026年限制性股票激励计划（草案）》及其摘要、《公司2026年限制性股票激励计划实施考核管理办法》及提请股东会授权董事会办理股权激励相关事宜的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400002545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688767"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664684537","title":"股市必读：博拓生物新发布《2026年第二次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664684537","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664684537?lang=zh_cn&edition=full","pubTime":"2026-09-03 01:49","pubTimestamp":1788371351,"startTime":"0","endTime":"0","summary":"公司公告汇总：博拓生物将于9月14日召开第二次临时股东会，审议2026年限制性股票激励计划相关议案。公司公告汇总2026年第二次临时股东会会议资料杭州博拓生物科技股份有限公司将于2026年9月14日召开第二次临时股东会，审议《公司2026年限制性股票激励计划（草案）》及其摘要、《公司2026年限制性股票激励计划实施考核管理办法》及提请股东会授权董事会办理股权激励相关事宜的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688767","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663507158","title":"博拓生物（688767）披露2026年半年度报告，8月31日股价上涨4.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663507158","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663507158?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:49","pubTimestamp":1788169768,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，博拓生物报收于38.61元，较前一交易日上涨4.35%，最新总市值为57.66亿元。该股当日开盘37.0元，最高39.39元，最低34.38元，成交额达1.3亿元，换手率为2.37%。近日，杭州博拓生物科技股份有限公司披露《2026年半年度报告》。利润总额为-23,622,640.42元，较上年同期下降288.26%。经营活动产生的现金流量净额为8,114,371.15元，较上年同期下降82.73%。研发投入占营业收入的比例为23.86%，较上年同期增加4.19个百分点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100025221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688767","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663047297","title":"股市必读：博拓生物中报 - 第二季度单季净利润同比下降272.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663047297","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663047297?lang=zh_cn&edition=full","pubTime":"2026-08-31 06:08","pubTimestamp":1788127695,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，博拓生物报收于37.0元，上涨0.82%，换手率1.29%，成交量1.93万手，成交额7102.2万元。业绩披露要点：2026年中报显示归母净利润为-1655.26万元，同比下降233.46%；第二季度扣非净利润同比下降1806.44%。其中第二季度主营收入1.25亿元，同比上升8.59%；归母净利润-634.47万元，同比下降272.88%；扣非净利润-785.49万元，同比下降1806.44%；负债率10.85%，投资收益-155.48万元，财务费用2032.25万元，毛利率47.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100001516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688767"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663455048","title":"博拓生物（688767）2026年中报简析：增收不增利，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2663455048","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663455048?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:19","pubTimestamp":1788041940,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期博拓生物发布2026年中报。截至本报告期末，公司营业总收入2.15亿元，同比上升5.61%，归母净利润-1655.26万元，同比下降233.46%。本报告期博拓生物三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达52.87%。持有博拓生物最多的基金为广发医药创新混合发起式A，目前规模为0.36亿元，最新净值1.0108，较上一交易日下跌1.57%，近一年下跌33.03%。本文数据来源于博拓生物2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688767"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663501012","title":"博拓生物(688767)6月30日股东户数0.64万户，较上期减少20.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663501012","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663501012?lang=zh_cn&edition=full","pubTime":"2026-08-29 17:11","pubTimestamp":1787994686,"startTime":"0","endTime":"0","summary":"证券之星消息，近日博拓生物披露，截至2026年6月30日公司股东户数为6405.0户，较3月31日减少1697.0户，减幅为20.95%。在医疗器械行业个股中，博拓生物股东户数低于行业平均水平，截至6月30日，医疗器械行业平均股东户数为2.09万户。从股价来看，2026年3月31日至2026年6月30日，博拓生物区间涨幅为6.42%，在此期间股东户数减少1697.0户，减幅为20.95%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900023337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688767"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663687018","title":"图解博拓生物中报：第二季度单季净利润同比下降272.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663687018","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663687018?lang=zh_cn&edition=full","pubTime":"2026-08-29 01:55","pubTimestamp":1787939717,"startTime":"0","endTime":"0","summary":"证券之星消息，博拓生物2026年中报显示，上半年度公司主营收入2.15亿元，同比上升5.61%；归母净利润-1655.26万元，同比下降233.46%；扣非净利润-2080.19万元，同比下降404.35%；其中2026年第二季度，公司单季度主营收入1.25亿元，同比上升8.59%；单季度归母净利润-634.47万元，同比下降272.88%；单季度扣非净利润-785.49万元，同比下降1806.44%；负债率10.85%，投资收益-155.48万元，财务费用2032.25万元，毛利率47.06%。财报数据概要请见下图:本文数据来源于博拓生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900005456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688767"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793909422136,"stockEarnings":[{"period":"1week","weight":0.0301},{"period":"1month","weight":-0.0383},{"period":"3month","weight":-0.0082},{"period":"6month","weight":-0.0521},{"period":"1year","weight":-0.0371},{"period":"ytd","weight":0.0424}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0396},{"period":"3month","weight":-0.0635},{"period":"6month","weight":-0.1172},{"period":"1year","weight":-0.0704},{"period":"ytd","weight":-0.0703}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州博拓生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7871人(较上一季度增加22.89%)","perCapita":"18972股","listingDate":"2021-09-08","address":"浙江省杭州市余杭区中泰街道富泰路17号","registeredCapital":"14933万元","survey":" 杭州博拓生物科技股份有限公司的主营业务是即时检测试剂及仪器的研发、生产与销售。公司的主要产品是药物滥用（毒品）检测系列、传染病检测系列、生殖健康检测系列、肿瘤标志物检测系列、心肌标志物检测系列、抗原/抗体生物原料、动物疾病检测平台系列、炎症系列、分子诊断平台系列。","listedPrice":34.55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博拓生物(688767)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博拓生物(688767)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博拓生物,688767,博拓生物股票,博拓生物股票老虎,博拓生物股票老虎国际,博拓生物行情,博拓生物股票行情,博拓生物股价,博拓生物股市,博拓生物股票价格,博拓生物股票交易,博拓生物股票购买,博拓生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博拓生物(688767)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博拓生物(688767)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}